E-ISSN 2231-3206 | ISSN 2320-4672
 

Technical Note

Online Publishing Date:
22 / 10 / 2013

 


Difluprednate in ophthalmic practice

Minal M Patel, Deepika Singhal.


Abstract
The present note deals with the use of drug difluprednate in ophthalmic practice. In last few years, prednisolone acetate and betamethasone are strong steroids in use. Currently, the most widely prescribed strong topical corticosteroids in the US is prednisolone acetate 1%. While it controls inflammation effectively, it has not been shown to consistently address postoperative pain and discomfort in a large clinical trial.3 Chances of side effects like ocular hypertension and cataract formation are higher with these steroids. In june 2008 difluprednate ophthalmic emulsion 0.05% was approved by the US Food and Drug Administration (FDA) for the treatment of inflammation and pain associated with ocular surgery. This was the first ophthalmic steroid approved by the FDA since 1973 as it is high in potency and has good safety profile as well as the ability to reduce postoperative pain.

Key words: Ophthalmic practice, Post Operative, Difluprednate


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Minal M Patel
Articles by Deepika Singhal
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. 2014; 4(1): 92-94. doi:10.5455/njppp.2014.4.280820132


Web Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. https://www.njppp.com/?mno=42457 [Access: March 14, 2024]. doi:10.5455/njppp.2014.4.280820132


AMA (American Medical Association) Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. 2014; 4(1): 92-94. doi:10.5455/njppp.2014.4.280820132



Vancouver/ICMJE Style

Minal M Patel , Deepika Singhal. Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol. (2014), [cited March 14, 2024]; 4(1): 92-94. doi:10.5455/njppp.2014.4.280820132



Harvard Style

Minal M Patel , Deepika Singhal (2014) Difluprednate in ophthalmic practice. Natl J Physiol Pharm Pharmacol, 4 (1), 92-94. doi:10.5455/njppp.2014.4.280820132



Turabian Style

Minal M Patel , Deepika Singhal. 2014. Difluprednate in ophthalmic practice. National Journal of Physiology, Pharmacy and Pharmacology, 4 (1), 92-94. doi:10.5455/njppp.2014.4.280820132



Chicago Style

Minal M Patel , Deepika Singhal. "Difluprednate in ophthalmic practice." National Journal of Physiology, Pharmacy and Pharmacology 4 (2014), 92-94. doi:10.5455/njppp.2014.4.280820132



MLA (The Modern Language Association) Style

Minal M Patel , Deepika Singhal. "Difluprednate in ophthalmic practice." National Journal of Physiology, Pharmacy and Pharmacology 4.1 (2014), 92-94. Print. doi:10.5455/njppp.2014.4.280820132



APA (American Psychological Association) Style

Minal M Patel , Deepika Singhal (2014) Difluprednate in ophthalmic practice. National Journal of Physiology, Pharmacy and Pharmacology, 4 (1), 92-94. doi:10.5455/njppp.2014.4.280820132